146 related articles for article (PubMed ID: 22006099)
1. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer.
Takeda Y; Shinzaki S; Okudo K; Moriwaki K; Murata K; Miyoshi E
Cancer; 2012 Jun; 118(12):3036-43. PubMed ID: 22006099
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin.
Shimomura M; Nakayama K; Azuma K; Terao N; Nishino K; Takamatsu S; Nakano M; Takahashi S; Kobayashi Y; Murata K; Kamada Y; Miyoshi E
Clin Chim Acta; 2015 Jun; 446():30-6. PubMed ID: 25861849
[TBL] [Abstract][Full Text] [Related]
3. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer.
Fujita K; Shimomura M; Uemura M; Nakata W; Sato M; Nagahara A; Nakai Y; Takamatsu S; Miyoshi E; Nonomura N
Prostate; 2014 Jul; 74(10):1052-8. PubMed ID: 24802742
[TBL] [Abstract][Full Text] [Related]
4. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions.
Kamada Y; Kinoshita N; Tsuchiya Y; Kobayashi K; Fujii H; Terao N; Kamihagi K; Koyama N; Yamada S; Daigo Y; Nakamura Y; Taniguchi N; Miyoshi E
Clin Chim Acta; 2013 Feb; 417():48-53. PubMed ID: 23262369
[TBL] [Abstract][Full Text] [Related]
5. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis.
Morishita K; Ito N; Koda S; Maeda M; Nakayama K; Yoshida K; Takamatsu S; Yamada M; Eguchi H; Kamada Y; Miyoshi E
Clin Chim Acta; 2018 Dec; 487():84-89. PubMed ID: 30189188
[TBL] [Abstract][Full Text] [Related]
6. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis.
Ueda M; Kamada Y; Takamatsu S; Shimomura M; Maekawa T; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kobayashi Y; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
Pancreatology; 2016; 16(2):238-43. PubMed ID: 26897254
[TBL] [Abstract][Full Text] [Related]
7. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures.
Miyoshi E; Nakano M
Proteomics; 2008 Aug; 8(16):3257-62. PubMed ID: 18646007
[TBL] [Abstract][Full Text] [Related]
8. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development.
Asazawa H; Kamada Y; Takeda Y; Takamatsu S; Shinzaki S; Kim Y; Nezu R; Kuzushita N; Mita E; Kato M; Miyoshi E
Clin Chem Lab Med; 2015 Jan; 53(1):95-102. PubMed ID: 25060348
[TBL] [Abstract][Full Text] [Related]
9. Identification of fucosylated haptoglobin as a novel tumor marker for pancreatic cancer and its possible application for a clinical diagnostic test.
Miyoshi E; Shinzaki S; Moriwaki K; Matsumoto H
Methods Enzymol; 2010; 478():153-64. PubMed ID: 20816478
[TBL] [Abstract][Full Text] [Related]
10. Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical investigation.
Nishino K; Koda S; Kataoka N; Takamatsu S; Nakano M; Ikeda S; Kamamatsu Y; Morishita K; Moriwaki K; Eguchi H; Yamamoto E; Kikkawa F; Tomita Y; Kamada Y; Miyoshi E
Oncotarget; 2018 Feb; 9(16):12732-12744. PubMed ID: 29560105
[TBL] [Abstract][Full Text] [Related]
11. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells.
Narisada M; Kawamoto S; Kuwamoto K; Moriwaki K; Nakagawa T; Matsumoto H; Asahi M; Koyama N; Miyoshi E
Biochem Biophys Res Commun; 2008 Dec; 377(3):792-6. PubMed ID: 18951869
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
Tawara S; Tatsumi T; Iio S; Kobayashi I; Shigekawa M; Hikita H; Sakamori R; Hiramatsu N; Miyoshi E; Takehara T
PLoS One; 2016; 11(3):e0151828. PubMed ID: 27002630
[TBL] [Abstract][Full Text] [Related]
13. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.
Kamada Y; Akita M; Takeda Y; Yamada S; Fujii H; Sawai Y; Doi Y; Asazawa H; Nakayama K; Mizutani K; Fujii H; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
PLoS One; 2013; 8(6):e66328. PubMed ID: 23805214
[TBL] [Abstract][Full Text] [Related]
14. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer.
Toiyama Y; Fujikawa H; Kawamura M; Matsushita K; Saigusa S; Tanaka K; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Int J Oncol; 2012 Feb; 40(2):560-6. PubMed ID: 22038159
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
17. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation.
Moriwaki K; Noda K; Nakagawa T; Asahi M; Yoshihara H; Taniguchi N; Hayashi N; Miyoshi E
Glycobiology; 2007 Dec; 17(12):1311-20. PubMed ID: 17884843
[TBL] [Abstract][Full Text] [Related]
18. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
20. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling.
Zhao YP; Ruan CP; Wang H; Hu ZQ; Fang M; Gu X; Ji J; Zhao JY; Gao CF
Cancer; 2012 Feb; 118(3):639-50. PubMed ID: 21853445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
